<DOC>
	<DOCNO>NCT00881946</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability repeat dose compound GSK2110183 subject hematologic cancer .</brief_summary>
	<brief_title>Repeat Dose Safety Study Compound Treat Hematologic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Written inform consent provide . 2 . Male female least 18 year age old . 3 . Histologically cytologicallyconfirmed diagnosis hematologic malignancy relapse refractory standard therapy , AND associate human immunodeficiency virus ( HIV ) infection solid organ transplant , include : chronic lymphocytic leukemia ( CLL ) , chronic myelogenous leukemia ( CML ) , multiple myeloma ( MM ) , nonHodgkin 's lymphoma ( NHL ) , Hodgkin 's lymphoma , Other hematologic malignancy exclude : acute leukemia type CML blast crisis myelodysplastic syndrome ( MDS ) myelofibrosis 4 . Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale 5 . Able swallow retain oral medication . 6 . Fasting serum glucose &lt; 126 mg/dL ( &lt; 7 mmol/L ) . 7 . Male subject female partner childbearing potential must prior vasectomy agree use adequate contraception time first dose study drug three month last dose study drug . 8 . A female subject eligible participate : Nonchildbearing potential Childbearing potential , negative serum pregnancy test screening period , agree use adequate contraception screen four week last dose study drug . 9 . Adequate organ system function 1 . Chemotherapy , radiotherapy , immunotherapy within 28 day ( 42 day prior nitrosoureas mitomycin C ) prior first dose study drug . 2 . Use investigational anticancer drug within 28 day five halflives , whichever longer , precede first dose study drug . 3 . Current use prohibit medication require medication treatment study drug . 4 . Current use anticoagulant therapeutic level within seven day prior first dose study drug , include warfarin , low molecular weight heparin direct thrombin inhibitor . Low dose ( prophylactic ) anticoagulant permit provide subject 's PT PTT meet entry criterion . 5 . Current use antiplatelet agent ( e.g . dipyridamole , clopidogrel ) aspirin ( 81 mg daily ) . 6 . Presence active gastrointestinal disease condition could affect gastrointestinal absorption ( e.g . malabsorption syndrome ) predispose subject gastrointestinal ulceration . 7 . Any major surgery within last four week . 8 . Unresolved toxicity ( except alopecia ) Grade 2 previous anticancer therapy unless agree Medical Monitor Investigator 9 . Previously diagnose diabetes mellitus ( Type 1 2 ) . 10 . Current use oral corticosteroid , exception inhale topical corticosteroid . 11 . Any serious unstable preexist medical , psychiatric , condition ( include lab abnormality ) could interfere subject safety obtain informed consent . 12 . Symptomatic untreated central nervous system ( CNS ) involvement hematologic malignancy ( include primary CNS lymphoma ) . 13 . Evidence severe uncontrolled systemic disease 14 . Known infection HIV , HBV HCV . 15 . QTc interval â‰¥ 470 msec . 16 . Other clinically significant ECG abnormality include 2nd degree ( Type II ) 3rd degree atrioventricular ( AV ) block . 17 . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting bypass graft within past six month . 18 . Class III IV heart failure define New York Heart Association ( NYHA ) functional classification system . 19 . Pregnant lactate female . 20 . Active drug alcohol abuse . 21 . History sensitivity heparin heparininduced thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>aggressive lymphoma</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>acute myeloid leukemia</keyword>
</DOC>